Blocking the survival of the nastiest by HSP90 inhibition

被引：9
|
作者：
Workman, Paul [1 ]
Clarke, Paul A. [1 ]
Al-Lazikani, Bissan [1 ]
机构：
[1] Inst Canc Res, Div Canc Therapeut, Canc Res UK Canc Therapeut Unit, London SW3 6JB, England
来源：
ONCOTARGET | 2016年 / 7卷 / 04期
关键词：
HSP90; CLONAL EVOLUTION; CANCER; RESISTANCE; THERAPY; MODELS;
D O I：
10.18632/oncotarget.6971
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
It is now recognised that genetic, epigenetic and phenotypic heterogeneity within individual human cancers is responsible for therapeutic resistance - knowledge that is having a profound impact on current thinking and experimentation. There has been concern that molecularly targeted therapy is doomed to failure, with resistant clones emerging in response to the Darwinian selective pressure of any drug treatment. However, two studies have shown that the evolution of drug resistance can be restrained by co-administration of a pharmacologic inhibitor of the HSP90 molecular chaperone.
引用
收藏
页码：3658 / 3661
页数：4
相关论文
共 50 条
  • [41] Effect of geldanamycin on transcription of Hsp90α and Hsp90β genes in brain of goldfish
    Morishige, Kota
    Kagawa, Nao
    ZOOLOGICAL SCIENCE, 2006, 23 (12) : 1212 - 1212
  • [42] Hsp90 inhibition protects against inherited retinal degeneration
    Aguila, Monica
    Bevilacqua, Dalila
    McCulley, Caroline
    Schwarz, Nele
    Athanasiou, Dimitra
    Kanuga, Naheed
    Novoselov, Sergey S.
    Lange, Clemens A. K.
    Ali, Robin R.
    Bainbridge, James W.
    Gias, Carlos
    Coffey, Peter J.
    Garriga, Pere
    Cheetham, Michael E.
    HUMAN MOLECULAR GENETICS, 2014, 23 (08) : 2164 - 2175
  • [43] Antiangiogenic effects associated with the inhibition of HSP90 in colorectal cancer
    Mahaseth, Hemchandra
    Nagaraju, Ganji Purnachandra
    Diaz, Roberto
    Taliaferro-Smith, LaTonia D.
    Landry, Jerome C.
    Saba, Nabil F.
    El-Rayes, Bassel F.
    CANCER RESEARCH, 2012, 72
  • [44] Investigating PARP inhibitor sensitisation by hyperthermia and HSP90 inhibition
    Abdulrahman, G. O.
    Davison, E.
    Matheson, E.
    Drew, Y.
    Curtin, N.
    Mukhopadhyay, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 600 - 600
  • [45] Inhibition of Hsp90 compromises the DNA damage response to radiation
    Dote, Hideaki
    Burgan, William E.
    Camphausen, Kevin
    Tofilon, Philip J.
    CANCER RESEARCH, 2006, 66 (08)
  • [46] Inhibition of Hsp90: a new strategy for inhibiting protein kinases
    Sreedhar, AS
    Soti, C
    Csermely, P
    BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2004, 1697 (1-2): : 233 - 242
  • [47] Disruption of zebrafish somite development by pharmacologic inhibition of Hsp90
    Lele, Z
    Hartson, SD
    Martin, CC
    Whitesell, L
    Matts, RL
    Krone, PH
    DEVELOPMENTAL BIOLOGY, 1999, 210 (01) : 56 - 70
  • [48] Inhibition of the NLRP3 inflammasome by HSP90 inhibitors
    Nizami, Sohaib
    Arunasalam, Kanisa
    Green, Jack
    Cook, James
    Lawrence, Catherine B.
    Zarganes-Tzitzikas, Tryfon
    Davis, John B.
    Di Daniel, Elena
    Brough, David
    IMMUNOLOGY, 2021, 162 (01) : 84 - 91
  • [49] Therapeutic Potential of HSP90 Inhibition for Neurofibromatosis Type 2
    Tanaka, Karo
    Eskin, Ascia
    Chareyre, Fabrice
    Jessen, Walter J.
    Manent, Jan
    Niwa-Kawakita, Michiko
    Chen, Ruihong
    White, Cory H.
    Vitte, Jeremie
    Jaffer, Zahara M.
    Nelson, Stanley F.
    Rubenstein, Allan E.
    Giovannini, Marco
    CLINICAL CANCER RESEARCH, 2013, 19 (14) : 3856 - 3870
  • [50] Persistent Activation of mRNA Translation by Transient Hsp90 Inhibition
    Tsvetkov, Peter
    Eisen, Timothy J.
    Heinrich, Sven U.
    Brune, Zarina
    Hallacli, Erinc
    Newby, Greg A.
    Kayatekin, Can
    Pincus, David
    Lindquist, Susan
    CELL REPORTS, 2020, 32 (06):
12345